Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Non-relapse Mortality for Myeloma CAR-T
Non-relapse Mortality for Myeloma CAR-T
Non-relapse mortality for myeloma patients undergoing CAR-T therapy is a serious side effect according to the article linked below.
Side effects are to be expected when you’re talking about cancer therapies. Especially with new therapies such as CAR-T cell therapy. My problem with oncology and CAR-T therapy is that positive feedback is everywhere. Negative results must be ferreted out like the information on non-relapse mortality for myeloma in the study discussed below.
This video is an example of what I’m talking about. Dr. Rejeski is comfortable tossing around acronyms (NRM, CAR-T, yada, yada) but nowhere does Dr. Rejeski mention that non-relapse mortality in myeloma CAR-T therapy is 6.8 percent according to the study below.
While this may seem like a small percentage of patients affected with NRM, remember that the study is talking about 7,604 MM patients dying from CAR-T cell therapy.
What is Non-relapse mortality in CAR-T Therapy?
Dr. Rajeski cites infection as the main cause of NRM in CAR-T therapy. Keep in mind that heavily treated RR/MM patients are usually the ones who turn to CAR-T therapy when they exhaust other forms of MM treatment. Heavily treated is another way of saying that their immune systems are possibly exhausted.
I am both a MM survivor and MM cancer coach. If you are considering CAR-T therapy, consider first undergoing evidence-based immune boosting therapies. A sort of pre habilitation for your immune system.
Email me at David.PeoplBeatingCancer@gmail.com with your questions about MM.
Hang in there,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
The risky side effects of CAR-T therapy
Chimeric antigen receptor T-cell, or CAR-T, therapy has been a promising immunotherapy for patients with blood cancers. However, this personalized treatment—which genetically modifies patients’ T cells to attack specific antigens—has side effects that can increase the risk of death from other causes.
Harvard Public Health spoke with David Cordas dos Santos, an instructor of medicine at Dana-Farber Cancer Institute and the lead author of a study on CAR-T patients who have died from other causes (called non-relapse mortality).
Why study this topic?
There has not been a comprehensive study of CAR-T cell therapy that calculates overall non-relapse mortality. If we can learn the cause of adverse events, what does that mean for patients and how can we use that information in the clinic?
What did you find?
We found the non-relapse mortality rate for patients with lymphoma and multiple myeloma one year after treatment was about 6.8 percent, which was higher than we expected. We identified 7,604 patients across 46 studies published through March 2024.
More than half of the patients died from infections. We looked for specific pathogens, and most of the known infection-related deaths reported were listed as caused by COVID-19. However, about two-thirds of the pathogens were not identified or not reported.
The second most common cause was death from a secondary malignancy, so another cancer had developed.
What would you like to see happen based on the study’s results?
We would like to see improved guidelines for clinicians who have patients on CAR-T cell treatment and raise awareness about the risk of infections and secondary malignancies. There also can be better patient education; if you have a fever, call your doctor immediately. We asked researchers to report these deaths in more detail in the future. Now we see that studies are starting to report this.”
Non-relapse mortality for myeloma CAR-T Non-relapse mortality for myeloma CAR-T